The US FDA has approved Veklury® (remdesivir; Gilead Sciences) for the treatment of coronavirus disease 2019 (COVID-19) in patients aged 12 years and older (weighing at least 40kg) requiring hospitalization. The approval was supported by data from three phase 3 trials in hospitalized patients with mild to severe COVID-19. The randomized, double-blind, placebo-controlled phase 3 ACTT-1 trial assessed 1062 hospitalized patients with COVID-19 who received either Veklury (n=541) or placebo (n=521) in addition to standard of care.
According to preliminary study findings presented at Kidney Week 2020 Reimagined, a virtual meeting sponsored by the American Society of Nephrology, Phosphate binders do not appear to substantially hinder absorption of hypoxia-inducible factor prolyl hydroxylase inhibitors. “These results suggest that [phosphate binder] use does not have a major impact on [hemoglobin] values during the 24-week study,” Dr Cizman’s team stated. “Results of ASCEND-D, an ongoing, phase 3 dialysis study of daprodustat compared with conventional treatment, are awaited to confirm these initial observations.”
Daan J. Reesink et.al. conducted a study to assess how a risk-calculator and bi-parametric MRI should be combined to decide on prostate biopsy, balancing cancer detection rates and diagnostic burden. The researchers concluded that Upfront bpMRI as a risk stratification tool outperforms risk-calculator in detecting significant disease. Applying the risk-calculator first to decide on performing an MRI, avoids 1 out of 2 MRIs, but up to 1 out of 5 significant cancers are missed.
Terry Zhu et.al. presented a case of a 2-month-old full-term female who presented with a large anterior sacral meningomyelocele resulting in transient obstructive uropathy with bilateral hydronephrosis and acute kidney injury. After initial bladder decompression and surgical resection of the meningomyelocele, there was spontaneous resolution of bladder function confirmed with urodynamics.
A study published in the Journal of the American College of Cardiology reports a higher prevalence of major arterial or venous thromboembolism, major adverse cardiovascular events and symptomatic venous thromboembolism in COVID-19 patients in spite of receiving routine thromboprophylaxis. The researchers came to the conclusion after collating data from 1114 patients who tested positive for COVID-19, treated either in ICU or a non-ICU setting or as an outpatient. It has been found that the probability of such events occurring in patients in the ICU is higher. The data points to a need for better risk stratification and intensified efforts in preventing such events.
Hussein Al-Mohamad et.al. presented the case of a 43-year-old female with a past medical history of Marfan Syndrome (MFS), who consulted her cardiologist after being diagnosed with an abdominal aortic dissection which showed up in an abdominal CT. The patient had no complaints of pain and was hemodynamically stable. Physical examination revealed several features typical to MFS. The patient underwent successful surgical repair of her abdominal aortic dissection via a minimally invasive open retroperitoneal approach.
Jan Minners et.al conducted a study to determine the incidence and potential risk factors of sudden cardiac death (SCD) in asymptomatic aortic stenosis (AS) patients. The study demonstrates that SCD in asymptomatic AS patients is comparable to that in the general population which leads to the conclusion that the disease per se does not cause SCD instead SCD could be related to left ventricular hypertrophy.
According to a study done on 510 patients at Weill Cornell Medicine and New York-Presbyterian has shown that signs of damage to the heart's right ventricle as revealed by an echocardiogram could be a strong predictor of the mortality risk in COVID-19 patients. The study found that patients with the damage are on an average two and a half times more likely to succumb to the disease. The findings of the study stress the importance of non-invasive cardiovascular imaging in COVID-19 cases.
NYU study is first to describe rates of physical, verbal, and reputational aggression by patients toward practicing dentists. Workplace violence toward health care professionals is both widespread and widely overlooked,” said Kimberly Rhoades, a research scientist in the Family Translational Research Group at NYU College of Dentistry and the study’s lead author. “The purpose of this study was to provide an initial estimate of rates of patient aggression in dental practices in the United States.”
Research suggests around 36% of patients around the world have moderate dental anxiety. Approximately 12% of patients have cancelled their dental appointment due to the feeling of nervousness. As per the author, a new way of conversing, such as simplifying into Lehman’s terms and using various imagery, has a calming effect on some patients. Showing them visual aids or short videos on the treatment is useful. Allowing time to discuss this with your patients also helps.